clevudine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
uridine derivatives used as antiviral agents and as antineoplastics 4394 163252-36-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clevudine
  • levovir
  • Molecular weight: 260.22
  • Formula: C10H13FN2O5
  • CLOGP: -0.94
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 99.10
  • ALOGS: -0.47
  • ROTB: 2

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.969 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 7.228 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.324 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 2.056 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 92.090 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 91.040 % Moderate 0.73
herg hERG pIC50 3.625 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 1.117 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 3.062 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 89.930 % Moderate 0.73
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PRKDC,TEK 18
kinase-selectivity-class GRK2,MAP2K6 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.905 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 0.631 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 93.420 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.228 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 94.460 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 1.081 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 94.900 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 92.140 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 933.254 uM Moderate 0.73

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AF12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:64951 anti-HBV agent

Related Drugs by ATC class:

J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 12 drugs
abacaviradefovir dipivoxildidanosineemtricitabineentecavirlamivudinestavudinetelbivudinetenofovir alafenamidetenofovir disoproxilzalcitabinezidovudine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.46 acidic
pKa2 11.79 acidic
pKa3 13.23 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D03537 KEGG_DRUG
C0045212 UMLSCUI
CHEBI:135964 CHEBI
CHEMBL458875 ChEMBL_ID
DB06683 DRUGBANK_ID
C034935 MESH_SUPPLEMENTAL_RECORD_UI
7684 INN_ID
IN51MVP5F1 UNII
73115 PUBCHEM_CID

Pharmaceutical products:

None